Biotech Experienced Directors Further Strengthen the Company LeadershipContinue reading
Category Archives: AZBio News
Immunotherapy: Cancer’s New Frontier
Your immune system never sleeps. Every moment of the day, immune cells monitor your body for disease, calling for backup when they detect a threat. It’s a system that works elegantly — most of the time. It’s not foolproof; if it were, we would never get cancer in the first place.
Fast Track to Discovery: Online Course Will Show Researchers How to Bring a Medical Product to Market in Record Time
Revolutionary Program is Meant to Accelerate Commercialization in Cardiovascular Therapeutics, Bringing New Treatments to Patients Faster and at a Reduced CostContinue reading
TGen launches new discovery platform to guard human health
Clinical Microbiome Services Center enhances TGen’s genomic analyses Continue reading
Applications close this week for Start Up Stadium at BIO 2018
Now in its fourth year, this area in the BIO Exhibition provides an exciting and interactive experience where investors provide live feedback and judge 6 minute pitches presented by start-up biotech companies.Continue reading
Opportunity Alert – NIH SBIR Programs and Deadlines
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, also known as America’s Seed Fund, are one of the largest sources of early-stage capital for technology commercialization in the United States. These programs allow US-owned and operated small businesses to engage in federal research and development that has a strong potential for commercialization.Continue reading
HonorHealth partners with Phoenix biotech startup for care innovation
Scottsdale-based HonorHealth and Phoenix-based NeoLight LLC are working together to advance technologies and innovation in the newborn care market. Under this new agreement, HonorHealth Research Institute will assess NeoLight’s medical technologies, starting with NeoLight’s portable Skylife phototherapy treatment device used to treat jaundice in newborns.
C-Path and CHDI launch consortium to accelerate development of Huntington’s therapies
The Critical Path Institute (C-Path), together with CHDI Foundation, Inc. (CHDI), today announced the official launch of C-Path’s Huntington’s Disease Regulatory Science Consortium (HD-RSC). In addition to these cofounders, the consortium also includes more than 20 different member organizations, including industry partners, academic institutions, and nonprofit societies. HD-RSC members will work to advance innovation in regulatory science methods, supporting clearer development and regulatory pathways that lead to the approval of Huntington’s disease (HD) therapeutics.